Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report)

Canadian Journal of Anesthesia

Volumn 61, Issue 8, 2014, Pages 727-735

  Karkouti, Keyvan ^a   Arellano, Ramiro ^b   Aye, Tim ^c   Dupuis, Jean Yves ^d   Kent, Blaine ^e   Lee, Trevor W R ^f   Lin, Yulia ^a   Ralley, Fiona ^g   MacAdams, Charles ^h   Mazer, C David ⁱ   Muirhead, Brian ^f   Rheault, Michel R ^j   Rochon, Antoine ^k   Syed, Summer ^l   Waters, Terrence ^m   Wong, Bill ⁿ  

^a UNIVERSITY OF TORONTO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c St Mary's Regional Cardiac Care Centre   (Canada)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

^f UNIVERSITY OF MANITOBA   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j LAVAL UNIVERSITY   (Canada)

^k MONTREAL HEART INSTITUTE   (Canada)

^l MCMASTER UNIVERSITY   (Canada)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG INDICATION; DRUG USE; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART SURGERY; HEMOPHILIA; HOSPITAL; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; PLASMA TRANSFUSION; PRIORITY JOURNAL; PROGNOSIS; REGISTER; RISK FACTOR; SINGLE DRUG DOSE; SURGICAL PATIENT; THROMBOCYTE TRANSFUSION; HEMORRHAGE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA;

AGED; CANADA; COHORT STUDIES; FACTOR VIIA; FEMALE; HEMORRHAGE; HEMOSTATICS; HOSPITALS; HUMANS; MALE; MIDDLE AGED; OFF-LABEL USE; RECOMBINANT PROTEINS; REGISTRIES;

EID: 84904542865     PISSN: 0832610X     EISSN: 14968975     Source Type: Journal    
DOI: 10.1007/s12630-014-0184-z     Document Type: Article

References (19)

1. Lloyd JV, Joist JH. Recombinant factor VIIa: a universal hemostatic agent? Curr Hematol Rep 2002; 1: 19-26.
2. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42: 114-24.
3. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med 2011; 154: 516-22.
4. Karkouti K, Beattie WS, Arellano R, et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation 2008; 118: 331-8.
5. Isbister J, Phillips L, Dunkley S, Jankelowitz G, McNeil J, Cameron P. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register. Intern Med J 2008; 38: 156-65. (Pubitemid 351271402)
6. Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011; 154: 529-40.
7. Avorn J, Kesselheim A. A hemorrhage of off-label use. Ann Intern Med 2011; 154: 566-7.
8. Lin Y, Moltzan CJ, Anderson DR, National Advisory Committee on Blood and Blood Products. The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework. Transfus Med 2012; 22: 383-94.
9. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358: 2127-37. (Pubitemid 351679599)
10. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-64. (Pubitemid 39620130)
11. Karkouti K, Levy JH. Recombinant activated factor VII: the controversial conundrum regarding its off-label use. Anesth Analg 2011; 113: 711-2.
12. Karkouti K, Beattie WS, Crowther MA, et al. The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference. Can J Anesth 2007; 54: 573-82.
13. Sorour Y, Van Veen JJ, Makris M. Recombinant factor VIIa for unlicensed indications - a definite No or a cautious Maybe in selected patients? Int J Clin Pract 2010; 64: 1468-71.
14. Guzzetta NA, Russell IA, Williams GD. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients. Anesth Analg 2012; 115: 364-78.
15. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013; 17: R76.
16. Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity-score matched case-control analysis. Transfusion 2005; 45: 26-34.
17. Andersen ND, Bhattacharya SD, Williams JB, et al. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations. Ann Thorac Surg 2012; 93: 1921-8.
18. The Society of Thoracic Surgeons Blood Conservation Guideline Task Force; Ferraris VA, Ferraris SP, Saha SP, et al.; Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83: S27-S86.
19. Menkis AH, Martin J, Cheng DC, et al. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. Innovations (Phila) 2012; 7: 229-41.